drugset / Trial / NCT01007864
Influence of Piribedil (Clarium®) on Vigilance and Cognitive Function in Patients With Parkinson's Disease Compared to Other Non-Ergot Dopamine Agonists
RandomizedParallel-groupSingle-blindTreatment
Summary
The purpose of this clinical trial is to investigate the effects of the non-ergot dopamine agonist piribedil on vigilance and cognitive performances in patients with Parkinson's disease in comparison with other oral non-ergot dopamine agonists. It should be tested whether piribedil is superior to continued pramipexole or ropinirole treatment regarding improvement of reduced vigilance and cognitive performance in patients with Parkinson's disease.
Timeline
- Start
- 2010-01
- Primary completion
- 2011-12
- Completion
- 2011-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Pramipexole | Unknown | — | — |
| Comparator | Ropinirole | Small molecule | — | — |
| Subject | piribedil | Small molecule | 100 mg | Oral |
| Subject | piribedil | Small molecule | 300 mg | Oral |